Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study

Authors: Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar, Valeria Magarotto, Xavier Leleu, Franck Morschhauser, Lionel Karlin, Florence Broussais, Keyvan Rezaï, Patrice Herait, Carmen Kahatt, François Lokiec, Gilles Salles, Thierry Façon, Antonio Palumbo, David Cunningham, Emanuele Zucca, Catherine Thiéblemont - The Lancet 2016 cited by 428